Radiotherapy (RT) Patterns of Care Study (PCS) in Lung Carcinoma
Reviewer: William Levin, MD
Last Modified: October 9, 2002
Presenter: B. Movsas
Presenter's Affiliation: Fox Chase Cancer Center (FCCC), Phila, PA, USA
Type of Session: Scientific
- This study was designed to determine the national patterns of radiation therapy (RT) practice in patients treated for non-metastatic lung cancer between 1998-1999.
Materials and Methods
- A survey of randomly selected RT institutions was conducted. Both academic and non-academic institutions were surveyed.
- Patients with non-metastatic lung cancer who received RT as definitive or adjuvant therapy were randomly selected.
- The charts of 541 patients were reviewed.
- 58 institutions were represented.
- 14.5% of histologies were small cell lung cancer (SCLC), while the remainder were non-small cell lung cancer (NSCLC).
- Median age was 67 years (37-92).
- 58% of patients were male, while 42% were female.
- 32% of patients were current smokers.
- 59% of patients had co-morbidities, mostly cardiopulmonary.
- KPS was >80 in 84% of patients.
- 98% of patients had staging CT scans.
- In CS III patients, bone scans and brain MRI's were not obtained in 33% and 52%, respectively.
- For NSCLC, a breakdown by clinical stage (CS) is as follows: CS I-12%, CS II-16%, CS III-54% (4% unknown).
- For patients with NSCLC, 31% had their mediastinums pathologically staged.
- Treatment strategies varied significantly by histology and stage.
- The majority of patients with SCLC and stage III NSCLCA received chemotherapy (CT) + RT.
- Most patients with CS I NSCLC received RT as their only treatment.
- Median dose for RT in the SCLC patients was 51 Gy, 80% at 1.8-2 Gy/fraction; 10% received hyperfractionated (b.i.d.) RT.
- 23% of these patients received prophylactic cranial irradiation (median dose, 30 Gy/15 fractions).
- For NSCLC, the median dose was 60 Gy, 85% @ 1.8-2 Gy/fraction.
- The majority of patients were treated with 6MV or 10 MV photons.
- CT-based treatment planning was used in 50% of patients.
- Maximum spinal cord dose was 41 Gy, although the dose was unknown in 29%.
- 57% of patients received systemic treatment.
- Surgery was performed in 28% of NSCLC patients.
- 5% of all patients were enrolled on cooperative trials, and 2% on institutional (IRB-approved) trials.
- This study establishes the general patterns of care for lung cancer in U.S. RT facilities.
- Better staging and documentation of spinal cord dose should be encouraged.
- The authors point out recent studies supporting the use of PCI and b.i.d. RT in SCLC have not had enough time to fully be reflected in a patterns of care study.
- Also, this study reveals that a small percentage of lung cancer patients are being enrolled on clinical trials.
Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.
Frequently Asked Questions
National Cancer Institute